Entrectinib price

Entrectinib (Entrectinib) is a new generation of targeted anti-tumor drugs that belongs to the class of multi-target tyrosine kinase inhibitors (TKI). Its development and application represent important progress in the field of tumor treatment.

Entrectinib has been launched in China, but due to its short time on the market, it has not yet been included in the medical insurance catalog. Since it has just been launched, it is difficult to purchase domestically and the price is very high. For specific prices, please consult the hospital pharmacy at that time. There are original drugs and generic drugs abroad. The original drugs abroad are mainly European versions of original drugs. The price is about 45,000 yuan. The price is relatively high and may be unaffordable for ordinary families. Generic drugs are mainly Lao generic drugs, with prices ranging from 4,000 to 8,000yuan, which are much cheaper than original drugs, and the ingredients of original drugs and generic drugs are basically the same.

Entrectinib’s mechanism of action is based on targeting tumor cells with specific genetic mutations. It is mainly used in malignant tumors carrying mutations such as NTRK gene fusion, ROS1 ROS1 gene fusion and ALK ALK gene fusion. By inhibiting abnormal signaling caused by these gene mutations, entrectinib can interfere with the growth, division and spread of tumor cells, thereby slowing down or even inhibiting tumor development.

The efficacy of entrectinib is closely related to whether the patient carries a specific gene mutation. Before use, genetic testing is required to determine whether the patient is suitable for treatment with the drug, allowing for a personalized treatment strategy. Entrectinib not only acts on a single molecular target, but can also interfere with multiple targets at the same time, improving the efficacy of tumors with different gene mutations. Entrectinib not only shows significant anti-tumor activity in neuroblastoma, but also shows potential in a variety of malignant tumors such as ROS1 and ALK positive non-small cell lung cancer.